Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient understands study requirements and has given his/her written informed consent on an Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approved consent form.~* Parkinson's disease diagnosis consistent with UK Parkinson's Disease Society Brain Bank Diagnostic criteria~* Minimum of 3 years since diagnosis.~* Meet Hoehn and Yahr PD stage~* Good response to levodopa~* Stable regimen of anti-PD medications~* Patients must have been taking a levodopa-containing anti-PD medication continuously for at least the previous 12 months~* Patient has documented a minimum amount of Off time.~* If of childbearing potential (male and female) must use an acceptable method of contraception~Exclusion Criteria:~* Previous tozadenant study participation~* Current or recent participation in another study.~* Secondary or atypical parkinsonism~* Neurosurgical intervention for PD (except DBS if electrode placement has been performed over 12 months prior to screening)~* Patient is taking apomorphine, budipine, istradefylline, tolcapone, or DUOPA™/Duodopa®~* Treatment with excluded medications~* Untreated or uncontrolled hyperthyroidism or hypothyroidism~* Clinically significant out-of-range laboratory~* MMSE out of range~* Current episode of major depression (stable treatment for depression is permitted).~* Recent suicide attempt or suicidal ideation type 4 or type 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS)~* Women lactating or pregnant~* Hypersensitivity to any components of tozadenant or excipients~* Abnormal findings on the physical or neurological examination, or medical history that would make the patient unsuitable for the study~* History of hepatitis or cholangitis

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tozadenant (Type: EXPERIMENTAL): 120 mg twice daily. At Week 2 or thereafter doses of 60 mg BID and 120 mg BID will be permitted.

Based on this trial design, predict the completion outcome and termination type (if applicable).